Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07172035

The Impact of Transjugular Intrahepatic Portosystemic Shunt on Recompensation in Patients With Decompensated Liver Cirrhosis

Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

View on ClinicalTrials.gov

Summary

The traditional view holds that the natural course of cirrhosis is a unidirectional process, characterized by irreversible progression from the compensated stage to the decompensated stage, and is highly likely to develop further decompensation events or even death. However, a growing body of evidence suggests that the natural course of cirrhosis is not always unidirectional - after the removal of the etiology, the structural and functional changes of the liver may be partially reversed. This understanding has given rise to the concept of "liver recompensation," which has been standardized at the Baveno VII Consensus Conference. Notably, in a cohort of patients with alcohol-related cirrhosis, 18% achieved recompensation, which was significantly associated with a reduction of more than 90% in liver-related mortality. In patients with hepatitis B-related cirrhosis, 6% achieved recompensation after treatment with nucleos(t)ide analogs, with a similar improvement in mortality. Transjugular intrahepatic portosystemic shunt (TIPS) is a well-established therapy for complications related to portal hypertension, including gastroesophageal variceal bleeding, refractory ascites, and hepatic hydrothorax. Compared with standard treatment, TIPS has been proven to reduce the incidence of further decompensation and improve transplant-free survival. However, due to portal blood shunting, the risks of abnormal liver function and hepatic encephalopathy (HE) also increase. It is worth noting that TIPS is not included in the definition of recompensation in the Baveno VII Consensus. Therefore, whether patients with cirrhosis who undergo TIPS treatment can achieve recompensation and which factors determine the probability of recompensation remain unknown. More importantly, the impact of recompensation on the risk of HCC development and mortality in TIPS patients has not been studied prospectively.

Official title: Transjugular Intrahepatic Portosystemic Shunt (TIPS) for Recompensation in Patients With Decompensated Cirrhosis: A Multicenter Prospective Cohort Study

Key Details

Gender

All

Age Range

18 Years - 80 Years

Study Type

OBSERVATIONAL

Enrollment

250

Start Date

2025-08-01

Completion Date

2027-08-01

Last Updated

2025-12-05

Healthy Volunteers

No

Locations (15)

Second Xiangya Hospital, Central South University

Changsha, China

The Third Xiangya Hospital of Central South University

Changsha, China

Fujian Medical University Union Hospital

Fuzhou, China

Huanggang Central Hospital

Huanggang, China

Jingzhou Central Hospital

Jingzhou, China

Jiangxi Provincial People's Hospital

Nanchang, China

The First Affiliated Hospital of Nanjing Medical University

Nanjing, China

Shengjing Hospital of China Medical University

Shenyang, China

Shanxi Provincial People's Hospital

Taiyuan, China

Renmin Hospital of Wuhan University

Wuhan, China

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Wuhan, China

Zhongnan Hospital of Wuhan University

Wuhan, China

Xiangyang Central Hospital

Xiangyang, China

Yichang Central People's Hospital

Yichang, China

The First Affiliated Hospital of Zhengzhou University

Zhengzhou, China